Syndax Pharmaceuticals' stock experienced a significant after-hours plunge of 6.67%, following the release of its first-quarter 2026 financial results.

The company reported a mixed earnings performance, with its loss per share of $(0.48) beating analyst estimates of $(0.64). However, quarterly sales of $64.864 million fell short of the consensus estimate of $70.439 million, representing a miss of approximately 7.91%.

While the company demonstrated substantial year-over-year revenue growth of over 223%, the sales shortfall appears to have prompted a negative reaction from investors in the after-hours session, leading to the sharp decline in share price.